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Summary: Liver damage and alterations in the exocrine function of the gland lead to a profound alteration of the
plasma lipoprotein profile. To determine whether hepatic disease results in changes in the lipoprotein fatty acid
composition, i. e. to determine whether liver function influences the homeostasis of complex lipids in plasma, we
studied the fatty acid profile of lipids from VLDL, LDL and HDL, as well as from total plasma, in thirty-one
patients of both sexes with hepatobiliary pathology (compensated liver cirrhosis, uncompensated liver cirrhosis,
primary biliary cirrhosis, other intrahepatic cholestasis, and acute viral hepatitis). We also studied a group of healthy
adults as controls. We present the lipoprotein profile and the fatty acid composition (myristic C14, palmitic C16,
palmitoleic C16 : 1, stearic CIS, oleic CIS : 1, linoleic CIS : 2, eicosatrienoic C20 : 3co6 and arachidonic C20 : 4)
of lipoprotein and total plasma triacylglycerols, cholesteryl esters and phospholipids. The main observation of this
study is that, despite the profound changes in the lipoprotein profile and the lower abundance of polyunsaturated
fatty acids in complex lipids, the composition of all triagylglycerols, cholesteryl esters and phospholipids is
very similar for the corresponding lipoproteins of patients with hepatobiliary disease and of control subjects.
This indicates that in the controls as in the studied patients, the exchange of lipids between plasmatic
lipoproteins is very rapid and demonstrates the possible importance of the extrahepatic synthesis of cholesteryl
ester transfer protein.
Introduction
The liver has a central role in the synthesis of polyunsat-
urated fatty acids and in lipoprotein metabolism. It is
site of synthesis of the greater part of arachidonic acid,
cholesterol, triacylglycerols, phospholipids and apoprot-
eins that circulate in plasma as lipoproteins. Liver also
produces and secretes lecithin : cholesterol acyltransfer-
ase2), a plasmatic enzyme that esterifies the cholesterol
collected from the cells by HDL (1), and cholesteryl
ester transfer protein which allows the exchange of neu-
tral lipids between the different classes of lipoproteins in
plasma (2). Liver damage and alterations in the exocrine
function of the gland lead to a profound alteration of the
plasma lipid profile, modifying the lipoprotein content
of total and esterified cholesterol, triacylglycerols, phos-
pholipids (3) and apolipoproteins (4), as well as the
activities of lecithin : cholesterol acyltransferase (5),
cholesteryl ester transfer protein (6,7) and hepatic lipase
!) This work was supported in part by the Fondo de Investigaci-
ones Sanitarias (94/0484), Spain.
2) Enzymes
Alkaline phosphatase (EC 3-1.3.1), Aspartate aminotransferase (EC
2.6.1.1), γ-Glutamyl transferase (EC 2.3.2.2), Lecithin : cholesterol
acyltransferase (EC 2.3.1.43).
(8). Liver damage also influences the transformations of
polyunsaturated fatty acids (9).
The fatty acid composition of plasma lipids is a reflec-
tion of the type of fatty acids in the diet, and of the
synthesis and transformation of fatty acids in the organ-
ism. The different classes of complex lipids — triacyl-
glycerols, cholesteryl esters and phospholipids — have
different compositions of fatty acids. The fatty acid
composition of these complex lipids in the different li-
poproteins has been studied in detail in healthy subjects,
and shown to be similar in VLDL, LDL and HDL (10—
11), thus confirming the rapid exchange of these lipids
between these lipoproteins, mediated by the transfer pro-
teins. In contrast, in animal species that lack cholesteryl
ester transfer protein, such as the rat and the pig, the
fatty acid profile of cholesteryl esters in the distinct lipo-
proteins is different (12-13).
In patients with liver diseases, especially those with cir-
rhosis, the fatty acid composition of triacyclglycerols,
cholesteryl esters and phospholipids from total plasma
is markedly different from that of healthy subjects (9,
14-15), but the fatty acid profiles of these lipid frac-
tions from the different lipoproteins have not been
studied. It is therefore necessary to determine the distri-
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bution of lipid species among the different lipoproteins
in hepatic disease. A non-homogeneous distribution
would reflect an alteration in plasmatic lipoprotein me-
tabolism.
All these data underline the influence of the functional
state of the liver on the availability of energy-yielding
substrates, and they indicate possible effects on the ac-
tivity of cholesteryl ester transfer protein.
In the present work, to determine the influence of the
liver function on the homeostasis of complex lipids in
plasma, we have studied the lipoprotein profile and the
fatty acid composition of lipids from VLDL, LDL and
HDL, as well as from total plasma, in several groups of
patients with hepatobiliary pathology.
the phospholipids, triacyclglycerols and cholesterol ester
were separated by thin layer chromatography, and their constituent
Sy adds were methylated before analysis with 4 ml of su^hunc
acid/methanol (1 + 2, by vol.) for 3 h at ^jSym^M
quantitation of fatty acids was accomplished at 180 C m a Perkm
Elmer 3920 Β gas liquid Chromatograph (Perkm Elmer Corp., Nor-
walk, CT), equipped with a 2 m X 2 mm I. D. glass column filled
with 5% of diethylene glycol succmate on gas chrom Q 100-120
mesh Quantitation was based on comparison of the relative re-
sponses of the fatty acid methyl esters in the sample with the re-
sponses of pure standards (Sigma, Chemical Co., Sigma-Aldnch
Quimica S.A.).
Statistical analysis
Fatty acid methyl esters (percentages) from the different lipopro-
teins and plasma lipid fractions were determined for each disease
and compared with those of the control group by the Newman
Keuls Hartley test.
Materials and Methods
Subjects
Thirty-six patients of both sexes, between the ages of 23 and 72 years
were studied. Twelve suffered from liver cirrhosis, in the majority of
cases of ethylic origin, that was uncompensated in 7 and compen-
sated in the rest. Fourteen had primary biliary cirrhosis, 8 in stages I
and II and the remaining in HI. The evolution of the disease in the
patients was from 1 to 10 years. Five patients presented other intra-
hepatic cholestasis distinct from primary biliary cirrhosis, 2 of scle-
rotic cholangitis and 3 of a pharmacological origin. In the other intra-
hepatic cholestasis group, the evolution of the disease was 1 to 10
months. Five patients presented acute viral hepatitis, and were
studied within 15 days of diagnosis. The age and sex distribution of
the 6 healthy adults comprising the control group were similar to
those of the patients. None was receiving medication or diet that
could alter the lipid metabolism or the fatty acids. All samples for
analysis were taken after fasting for 12 hours.
Isolation of l ipoproteins and l ipid analysis
Biood was withdrawn from patients and controls after a 12 hour
period of fasting. Blood was collected over EDTA · Na2 (1 g/1) and
rapidly centrifuged at 4 °C for plasma separation. Lipoproteins3)
were isolated from a 10 ml plasma aliquot by sequential ultracen-
trifugation with a Beckman 50 Ti rotor in a Beckman L5-50 ultra-
centrifuge (Beckman Instruments, Palo Alto, CA), as described
(18), at the following density ranges: very low-density lipoproteins
(VLDL), d < 1.006 kg/I; low-density lipoproteins (LDL), d 1.006
to 1.063 kg/1; high-density lipoproteins (HDL), d 1.063 to 1.21
kg/1. All salt solutions for density adjustment contained 1 mmol/1
EDTA · Na2. The lipoprotein-containing supematants were used for
lipid analysis and determination of fatty acid profile without any
further manipulation. Total cholesterol, free cholesterol, triacyl-
glycerols and phosphatidylcholine were measured enzymatically in
an autoanalyser Technicon RA-1000 (Technicon Ltd., Dublin, Ire-
land). Esterified cholesterol was calculated as the difference be-
tween total and free cholesterol. Glycerol was measured in depro-
teinized plasma (19) and this value was subtracted from those of
triacyclglycerols in total plasma and in lipoprotein fractions. Total
bilirubin, and albumin concentrations, as well as aspartate amino-
transferase2), γ-glutamyl transferase2), and alkaline phosphatase2)
activities were measured in serum in an Hitachi 747 autoanalyser.
Fatty acid profile analysis
Lipids were extracted from lipoprotein fractions and total plasma
with chloroform/methanol (2 + 1, by vol.), (16). After extraction,
3) Lipoproteins VLDL, very low-density lipoproteins, (d < 0.006
kg/1); LDL, low-density lipoproteins, (d = 1.006-1.063 kg/1);
HDL, high-density lipoproteins, (d = 1.063-1.21 kg/1).
Results
Table 1 presents the general biochemical profile of the
different groups of patients, and includes the results of
the serum monitoring of aspartate aminotransferase, γ-
glutamyl transferase, and alkaline phosphatase activities,
and total bilirubin and albumin concentrations. In the
profiles of the two cirrhotic patient subgroups, the hypo-
albuminaemia and increase of bilirubin in the metaboli-
cally uncompensated is notable, compared with the val-
ues for the compensated clinical state. The other bio-
chemical quantities serving as indicators of the liver
function were altered in the two subgroups, but with
a greater statistical significance in the more seriously
ill patients.
In the group of patients with intrahepatic cholestasis,
there was a significant increase in the total bilirubin con-
centration, except in those included in subgroup primary
biliary cirrhosis with primary, as yet incipient biliary
cirrhois (stages I and II). The greatest alteration in the
liver enzyme activities and increase of total bilirubin
were found in the patients with primary biliary cirrhosis
in stage III, compared with the other groups. The profile
of those suffering from other intrahepatic cholestasis
was the least altered in comparison with the controls.
The lipoprotein profiles of all the groups are summa-
rized in table 2; those of the patients with primary biliary
cirrhosis I and II are most similar to those of the con-
trols. In the patients with liver cirrhosis (uncompensated
liver cirrhosis and compensated liver cirrhosis), the most
remarkable observation was the low levels of triacycl-
glycerols with normal levels of cholesterol in total
plasma. In these cases, the lipoprotein profile showed a
reduced number of VLDL particles, as indicated by the
diminished content of both triacyclglycerols and choles-
terol in this fraction, and the presence of LDL enriched
with respect to triacylglycerols. In addition, HDL-cho-
lesterol was decreased in the uncompensated liver cir-
rhosis group. In patients with acute viral hepatitis, and
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Tab. 1 Hepatic function tests of patients with hepatobiliary dis- Serum samples were used for the evaluation of hepatic properties
eases and controls. by routine analyses.
Uncompen-
sated liver
cirrhosis
(n = 7)
Compen-
sated liver
cirrhosis
Primary
biliary
cirrhosis in
stages I, II
(n = 8)
Primary
biliary
cirrhosis in
stage HI
Acute
viral
hepatitis
Other
intrahepatic
cholestasis
(n = 5) (n = 5)
Controls
(n = 6)
Aspartate amino-
transferasea'b (U/l)
γ-Glutamyl
transferasea-b (U/l)
97±74C 73 ±49° 118±29e 187±139C 931±637C 56±24C 18 ±8
132±78d 119 ±85 272±155d 372±284d 152±84d 64 ±27 23 ±18
Alkaline phos-
phatase^b (U/l)
Bilirubina-b
(μπιοΐ/ΐ)
Albumin0· b (g/1)
329 ± 125C
97 ± 22e
26±3d
354 ± 298
32 ±21
38 ±2
875 ± 589C
43 ±39
-
2093 ±1691°
132±99C
-
427±168C
270±157d
-
316 ±223
108±82C
-
160 ±87
14±9
41±6
8
 Means ± S.D. d p < 0.01, e p < 0.001.
b
 Significant differences between groups and control atc ρ < 0.05,
Tab. 2 Serum lipoprotein lipids of patients with hepatobiliary Plasma samples were subjected to sequential ultracentrifugation for
diseases and controls. lipoprotein isolation, and the lipid composition was evaluated by
enzymatic analyses.
Uncompen- Compen- Primary
sated liver sated liver biliary
cirrhosis cirrhosis cirrhosis in
stages I, II
(n = 7) (n = 5) (n = 8)
Total cholesterol8* b 4.40 ± 1 .45 4.06 ± 1 .40 5.20 ± 0.98
(mmol/1)
Free cholesterol8·1» . 1.64 ±0.80 1.36 ±0.49 1.54 ±0.32
(mmol/1)
Esterified choles- 2.45 ± 0.78 2.72 ± 0.50 3.66 ± 1 .03
terola-b (mmol/1)
Fraction of esteri- 64 ±9 67 ±5 71±7
fied cholesterol8'0 (%)
Triacylglycerolsa'b 0.80±0.30d 0.65±0.11d 0.95 ± 0.29
(mmol/1)
LDL,cholesterola*b 3.40 ± 1.62 2.66 ± 1.09 3.50 ± 0.72
(mmol/1)
LDL-triacylglyc- 0.47 ± 0.22d 0.32 ± 0.09d 0.32 ±0.15
erolsa*b (mmol/1)
HDL-choles- 0.67±0.86d 1.14 ±0.49 1.37 ±0.57
terola-b (mmol/1)
HDL-triacylglyc- 0.09 ±0.06 0.13 ±0.05 0.14 ±0.05
erolsa-b (mmol/1)
VLDL-cholestes- 0.08 £ 0.05e 0.05 ± 0.03e 0. 1 6 ± 0. 13
terola-b (mmol/1)
VLDL-triacylglyc- 0.14±0.08e 0.14±0.10C 0.29 ±0.16
erolsa'b (mmoi/1)
Primary Acute Other Controls
biliary viral intrahepatic
cirrhosis in hepatitis cholestasis
stage III
(n = 6) (n = 5) (n = 5) (n = 6)
7.84±3.48C 5.30 ±1.80 4.81 ±0.50 4.89 ±1.18
3.56 ±3.22 2.28±0.65C 1.72 ±0.88 1.36 ±0.41
4.25 ±1.36 2.83 ±1.86 3.10 ±1.78 3.46 ±0.93
63±25 52±19C 44±16 72±4
1.50 ±0.82 3.06±0.87e 2.58 ±1.53 1.15 ±0.23
6.00 ±3.43 3.94 ±1.80 3.56 ±1.64 3.37 ±0.70
0.58 ± 0.48 1 .76 ± 0.64e 0.82 ± 0.53 0. 1 5 ± 0.03
1.55 ±0.49 0.72±0.28C 0.49±0.18d 1.09 ±0.21
0.25±0.10C 0.17 ±0.06 0.11 ±0.05 0.11 ±0.02
0.30 ±0.23 0.49±0.01d 0.65 ±0.72 0.23 ±0.03
0.62 ±0.50 0.83 ±0.45 1.11 ±0.39 0.64 ±0.1 7
a
 Mean ± S.D. d p < 0.01, e p < 0.001.
b
 Significant differences between groups and control atc ρ < 0.05,
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less notably in patients with other intrahepatic cholesta-
sis, the triacyclglycerol concentration in total plasma
was markedly elevated, whereas that of cholesterol was
within the normal range. This corresponded to an eleva-
tion of VLDL of normal composition and the presence
of LDL enriched with respect to triacyclglycerols. In
these two groups, the HDL-cholesterol concentration
was significantly lower than in controls. The patients
with primary biliary cirrhosis in stage III showed no
apparent change in the lipoprotein triacylglycerol
content, but showed major alterations in cholesterol me-
tabolism, as indicated by the increase in cholesterol con-
centration in total plasma and in LDL. This increase cor-
responded mainly to free cholesterol. A similar situation
was found in patients with acute viral hepatitis, which
probably reflects the deficiency of lecithin : cholesterol
acyltransferase activity characteristic of these diseases
(6).
The percentages of the fatty acids4)-myristic (C14), pal-
mitic (C16), palmitoleic (C16: 1), stearic (CIS), oleic
(CIS : 1), linoleic (CIS : 2), eicosatrienoic (C20 : 3ω6),
arachidonic (C20 :4) acids — in lipoprotein and total
plasma triacylglycerols, cholersteryl esters and phospho-
lipids are summarized in tables 3, 4 and 5, respectively.
In each group of patients the fatty acid composition of
triacylglycerols, cholesteryl esters and phospholipids
was very similar for VLDL, LDL, HDL and total
plasma, but there were significant differences between
each group of patients and between patients and the con-
trol group. Generally, the cholesteryl ester fraction was
the most sensitive, showing differences in fatty acid
composition in all the patient groups with respect to con-
trols, whereas the changes were more moderate in the
phospholipids. When all the patient groups are consid-
ered together, it appears that the content of the polyun-
saturated CIS : 2 and C20 :4 is lower than in controls,
a change that is compensated by moderate increases in
the other fatty acids. The most important changes were
observed in patients with liver cirrhosis, especially in
those with uncompensated liver cirrhosis, where the li-
noleic acid content of total plasma cholesteryl esters was
41.6%, compared with 58.3% in the controls
(p < 0.001) (tab. 4). The corresponding values for ar-
achidonic acid were 3.2 and 4.6%, respectively
(p < 0.05) (tab. 4). Among the other groups of patients,
acute viral hepatitis was the most similar to the uncom-
pensated liver cirrhosis, and therefore different from the
controls. Patients with other intrahepatic cholestasis also
showed significantly lower contents of linoleic acid in
the three lipid fractions of lipoproteins and total plasma
than the control group. The patients with primary biliary
cirrhosis had a more dispersed fatty acid profile, and the
4) Fatty acids are designated by the number of carbon atoms fol-
lowed by the number of double bonds.
differences from the control group were less significant.
Finally, more moderate differences were found in the
subgroup of primary biliary cirrhosis I and II.
Discussion
This study documents the lipoprotein profile and the
fatty acid composition of triacylglycerols, cholesteryl
esters and phopsholipids from VLDL, LDL, HDL and
total plasma in patients suffering from hepatic disease,
with distinct types of intrahepatic ch'olestasis, as com-
pared with control subjects. The main observation of the
present study is that in patients with hepatobiliary dis-
ease, despite the profound changes in the lipoprotein
profile and the lower abundance of polyunsaturated fatty
acids in complex lipids, the fatty acid composition of
all triacylglycerols, cholesteryl esters and phospholipids
was very similar among the different lipoproteins and in
control subjects. This indicates that in the controls, as
well as in the studied patients, the cholesteryl ester
transfer protein-promoted exchange of lipids between
plasmatic lipoproteins is very rapid, resulting in an
homogeneous distribution of lipid species between lipo-
protein particles.
Apart from the liver, other tissues also synthesize
cholesteryl ester transfer protein mRNA and secrete
active protein (21, 22), so that plasma cholesteryl ester
transfer protein may be derived from more than one
source. In this context, it is worth mentioning that in
chronic hepatitis, there is a marked decrease in plasma
lecithin : cholesterol acyl transferase activity, an enzyme
of exclusive hepatic origin, whereas plasma cholesteryl
ester transfer protein activity and mass remain stable (6),
which indicates that liver damage is not necessarily ac-
companied by changes in plasma lipid transfer activity.
Therefore, it is veiy likely that the cirrhotic patients
studied in this work had a normal cholesteryl ester
transfer protein activity, so that the velocity of the inter-
change of neutral lipids between the different classes of
lipoproteins was unaffected.
We consider next the difference in fatty acid composi-
tion between the complex lipids in cirrhotic patients and
those in normal individuals. In general, a diminution of
the polyunsaturated fatty acids CIS : 2 and C20 : 4 was
observed, which was more pronounced in the patients
with uncompensated liver cirrhosis or acute viral hepati-
tis. Compared with the controls, the triacylglycerols of
these patients contain in smaller percentage of CIS : 2,
the phopholipids are lower in C20 :4, while both fatty
acids are decreased in the cholesteryl esters. These lower
levels are compensated by a slight increase in the rest
of the fatty acids. We should point out that this fatty acid
profile, both in the control group and in the patients, is
similar to that found by other authors in population
groups in our geographical area (16, 17, 23). The com-
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position of fatty acids in cirrhotic patients resembles that
found in situations of linoleic acid deficiency (24-27).
It is known that patients with hepatobiliary disease suf-
fer frequently from an anorexic, emetic and nauseous
state, which in chronic situation can lead to severe mal-
nutrition (28). In fact, the anthropometric estimation
(29) of the two cirrhotic subgroups (data not shown)
indicated that 50% of the uncompensated were clearly
undernourished, while the rest were poorly nourished.
Also, these data agree with the lower percentage of lino-
leic acid in triacylglycerols, which is used to evaluate
the content of this fatty acid in the dietary fat (30). The
compensated cirrhotic patient presumably had a better
nutritional state, but this quantity fluctuated more in this
subgroup, possibly reflecting a greater alimentary
heterogeneity and subjacent liver damage, in spite of the
fact that this clinical state is more benign.
In patients with intrahepatic cholestasis, acute viral hep-
atitis and other intrahepatic cholestasis, we observed that
the relative content of linoleic acid was decreased in
parallel with the degree of cholestasis and the severity
of the hepatic disease. In the subgroups primary biliary
Tab. 3 Fatty acid composition of triacylglycerols from total
plasma and lipoproteins in patients with hepatobiliary diseases
and controls.
Plasma samples were subjected to sequential ultracentrifugation for
lipoprotein isolation. The lipids were extracted and separated by
TLC and the fatty acid composition was evaluated as methyl esters
by GLC.
Uncompen-
sated liver
cirrhosis
(n = 7)
Compen-
sated liver
cirrhosis
(n = 5)
Primary
biliary
cirrhosis in
stages I, II
(n = 8)
Primary
biliary
cirrhosis in
stage III
(n = 6)
Acute
viral
hepatitis
(n = 5)
Other
intrahepatic
cholestasis
(n = 5)
Controls
(n = 6)
Myristic acid C14 : 0 (%)a
VLDL 1.3 ±0.2
LDL 1.3 ±0.2
HDL 2.3 ±1.8
Total plasma 1.8 ±0.7
Palmitic acid C16:0(%)a
VLDL
LDL
HDL
Total plasma
28.4 ±3.8
25.5 ± 3.9
25.7 ± 5.5
27.3 ± 4.6
Palmitoleic acid C16 : 1 (%)a
VLDL 4.1 ±0.9
LDL 4.8 ±1.2
HDL 5.2 ± 2.0
Total plasma 5.1 ± 1.7
StearicacidC18:0(%)a
VLDL 6.6 ± 0.7e
LDL 5.8 ± 0.9e
HDL 6.2 ± 0.5C
Total plasma 5.3 ± 0.9e
Oleic acid CIS: 1 (%)a
VLDL 47.3 ± 2.5
LDL 50.8 ± 4.7
HDL 46.0 ± 6.7
Total plasma 50.2 ± 3.8
Linoleic acid C18 : 2 (%)a
VLDL 10.9±2.5e
LDL 10.4±2.6C
HDL 11.6±5.5e
Total plasma 9.6±3.0e
2.4±1.0d
1.1 ±0.2
1.6 ±0.4
1.6±0.1
26.2 ± 2.0
24.8 ±3.1
25.0 ±1.7
25.8 ± 2.2
4.0 ±1.2
4.0 ±1.6
4.5 ±1.5
4.7 ±1.0
5.8±1.2C
4.5 ±1.8
6.4 ±2.8
4.3 ±1.6
45.2 ±4.1
50.2 ±4.9
48.5 ± 6.6
49.3 ± 3.4
15.6 ±12.6
14.4 ±7.13
12.4±4.6d
13.0±3.0d
1.7±0.4C
1.3 ±0.5
1.4 ±0.6
1.2 ±0.4
26.3 ±4.5
25.4 ± 4.9
24.9 ±4.7
26.9 ± 6.8
4.6 ±1.4
3.9 ±1.4
4.7 ±1.9
4.6 ±1.8
4.0 ±1.1
4.9 ± 0.7C
4.6 ±1.3
4.7±1.0C
40.8 ± 4.3
43.0 ±4.8
43.2 ± 3.5
42.9 ± 6.0
21.8 ±7.2
20.4 ± 7.3
20.2 ± 6.8
19.1 ±7.7
1.8 ±0.9
1.9±1.1
2.2 ±1.6
2.0 ±0.9
25.3 ±1.8
25.0 ±3.3
25.1 ±4.5
26.3 ± 4.5
4.2 ±1.4
4.6 ±3.7
3.7 ±1.9
5.1 ±3.0
3.7 ±1.4
4.2 ±1.3
7.6 ± 0.5
3.7 ± 0.8C
41.2 ±7.9
39.8 ± 7.3
35.4±4.2C
40.0 ±5.8
22.0 ± 9.4
22.4 ±8.9
23.8 ±8.8
21.0 ±10.5
2.1 ±1.6
2.6 ±2.4
2.3 ±1.1
2.4 ±1.3
27.1 ±3.5C
28.1±4.6C
26.9 ± 3.2
27.5 ± 3.8
5.2 ±3.0
6.0±1.8C
4.8 ±2.7
4.8 ±2.0
5.4 ± 2.3C
6.2 ± 2.5
6.1 ±0.8°
5.5 ±1.9
42.3 ±4.1
42.3 ±4.1
40.8 ± 8.9
40.2 ± 7.5
18.05±5.4C
14.3 ±6.2
17.5±3.7C
17.7 ±5.6
1.9±0.7C
1.3 ±0.6
1.3 ±0.7
1.8 ±0.4
27.2 ± 3.3
24.1 ±4.3
24.2 ± 5.4
26.8 ± 4.5
5.0 ± 2.4
4.0 ±1.8
4.9 ± 2.8
4.6 ±3.0
3.0 ±0.8
3.7 ±0.5
4.6 ±1.0
3.8 ± 0.9
44.6 ±6.1
48.6 ± 6.5
47.2 ±7.1
46.7 ± 4C
17.5 ±5.7
16.9 ±5.9
17.9 ±6.8
16.2 ±4.6
1.1 ±0.2
0.8 ± 0.2
1.0 ±0.4
1.2 ±0.4
22.9 ± 2.6
21.9 ±2.3
22.8 ± 2.0
23.7 ± 2.4
4.0 ± 0.4
3.5 ±0.4
4.0 ± 0.4
4.3 ± 0.2
3.0 ±0.8
3.6 ±0.3
4.3 ±1.0
2.7 ± 0.2
44.1 ±3.3
44.6 ± 3.6
43.2 ±4.1
43.2 ±1.8
25.7 ± 3.4
24.5 ± 5.5
23.4 ±4.8
24.2 ± 3.6
Arachidonic acid C20 : 4 (%)a
VLDL
LDL
HDL
Total plasma
1.3 ±1.3
1.4 ±0.9
2.2 ±1.8
1.5 ±0.4
1.4±1.1
0.9 ± 0.3
1.4±1.3
1.3 ±0.4
0.6 ± 0.5
0.9 ±1.1
0.8 ± 0.7
0.5 ± 0.3
1.1 ±0.5
1.3±1.1
l.7±1.8
1.3 ±1.0
1.3 ±0.9
1.2±1.1
i.2±0.7
1.1 ±0.8
0.77 ± 0.2
1.2 ±0.5
1.2 ±1.0
0.5 ± 0.2
1.0 ±0.5
1.3 ±0.5
1.0 ±0.5
0.7 ± 0.2
a
 Values are means ± S.D. Significance differences between groups and control at c p < 0.05,
d p < 0.01, e p < 0.001.
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cirrhosis II and primary biliary cirrhosis in stage III,
however, the percentage of linoleic acid was maintained
within the control group range, although with rather
high interindividual dispersion. The fact that these pa-
tients with primary biliary cirrhosis did not lose appetite
even in severe jaundice, (31) together with the diet in
polyunsaturated fats they were recommended to take for
their chronic hypercholesterolaemia (32), probably con-
tribute to the unaltered content of linoleic acid observed
in primary biliary cirrhosis in stages I and II and primary
biliary cirrhosis in stage III patients.
The primary role of the liver in the synthesis of arachi-
donic acid is reinforced in the present study, which
clearly documents the low content of this fatty acid in
patients with hepatocellular damage. Interestingly, these
data contrast with the increase of arachidonic acid in
cystic fibrosis without liver affectation (29), probably as
a compensating effect of the diminution of its metabolic
precursor - linoleic acid - which is characteristic of
this disease (33).
The changes observed in the lipoproteins deserve some
comment. Patients with severe choiestasis, acute viral
Tab. 4 Fatty acid composition of cholesteryl esters from total
plasma and lipoproteins in patients with hepatobiliary diseases
and controls.
Plasma samples were subjected to ultracentrifugation for lipopro-
tein isolation. The lipids were extracted and separated by TLC and
the fatty acid composition was evaluated as methyl esters by GLC.
Uncompen-
sated liver
cirrhosis
(n = 7)
Compen-
sated liver
cirrhosis
(n = 5)
Primary
biliary
cirrhosis in
stages I, II
(n = 8)
Primary
biliary
cirrhosis in
stage III
(n = 6)
Acute
viral
hepatitis
(n = 5)
Other
intrahepatic
choiestasis
(n = 5)
Controls
(n = 6)
Myristic acid C14 : 0 (%)a
VLDL 1.5 ±0.1
LDL 1.0 ±0.1
HDL 1.3 ±0.7
Total plasma 0.9 ± 0.3C
Palmitic acid C16 : 0 (%)a
VLDL
LDL
HDL
Total plasma
15.0±1.0e
14.3±1.5d
15.0±2.0e
15.0 ± 0.9d
Palmitoleic acid C16 : 1 (%)a
VLDL 5.0 ± 0.9
LDL 5.7±1.6C
HDL 6.5 ± 2.2d
Total plasma 5.3 ± 0.9
StearicacidC18:0(%)a
VLDL 2.6 ± 0.7
LDL 2.7 ± 0.2d
HDL 3.2±1.5d
Total plasma 2.2 ± 0.9C
01eicacidC18: 1 (%)
VLDL 33.6 ± 4.7C
LDL 33.2 ± 6.8d
HDL 33.2 ± 4.4d
Total plasma 32.1 ±5.1d
Linoleic acid CIS: 2 (%)a
0.7 ± 0.2
0.7 ± 0.5
0.5 ± 0.3
1.0±0.3C
13.7 ±3.0
15.6 ±5.0
15.8 ±5.3
14.4 ±3.6
3.3 ±1.0
3.1 ±1.9
3.6 ±1.9
3.2 ±1.6
2.4 ± 0.9
3.1 ±2.5
3.2 ±2.2
2.8 ±1.7
27.2 ± 6.0
26.3 ± 7.5
26.2 ± 7.7
25.9 ± 5.0
0.5 ± 0.4
0.5 ±0.1
0.5 ± 0.3
0.5 ± 0.3
12.4±1.8C
12.5 ±1.5
12.1 ±1.6
12.7 ±2.6
3.6 ±3.7
3.5 ±2.5
3.7 ±4.6
4.1 ±3.8
0.9 ± 0.5
0.8 ± 0.3
1.0 ±0.2
0.9 ± 0.3
23.7 ± 7.7
21.1 ±4.9
21.0 ±5.7
21.5 ±5.8
0.5 ± 0.2
0.5 ±0.1
0.7 ±0.3
0.6 ± 0.2
11.8±1.5
11.0 ±0.8
12.5 ±1.0
7.9±4.6C
7.5 ±5.5
6.1 ±4.0
6.2 ±4.9
0.8 ± 0.3
0.8 ±0.5
1.1 ±0.2
0.9 ± 0.4
20.5 ± 4.0
19.8 ±5.4
15.3 ±2.9
20.5 ± 5.0
2.0 ±1.5
1.0 ±0.7
2.6±1.2C
1.8±0.5C
17.2±4.3C
13.9±1.2C
16.6±4.4C
15.8±1.6C
7.7±5.1C
8.4 ± 4.6C
6.9 ± 3.8
8.1±4.3C
3.4:
1.8:
3.7:
2.4:
23.8:
22.7:
24.0:
23.8:
:0.8
:2.2C
:0.4C
:6.5
:5.5
:4.3
:5.6
VLDL
LDL
HDL
Total plasma
Arachidonic acid
VLDL
LDL
HDL
Total plasma
39.9 ± 8.3C
41.5±8.1d
37.0 ± 7.2e
41.6±4.2C
C20 : 4 (%)a
3.0 ± 1.2C
3.6 ± 1.3d
4.1±1.7e
3.2±1.5C
52.3 ± 9.0
46.4 ±12.7
45.7 ±13.5
49.1 ±11. 4
3.8 ±1.0
4.7±1.4C
4.3±1.4d
4.0 ± 1.0C
56.9 ±12.2
55.5 ± 9.9
55.1 ±11.0
56.9 ±13.2
5.2 ±2.7
5.7 ±2.0
6.3 ±2.4
5.3 ±1.2
48.9 ± 7.9
54.7 ± 9.2
58.6 ± 6.4
53.2 ± 8.7
5.2 ± 2.3
6.2 ±2.1
6.3 ±1.6
5.7+1.7
36.1±8.2d
42 7 + 6 8C
37.6 ±11. 3'
42.2 ± 3.9d
3.9 ± 0.5C
5.2±1.0C
5.1 ±1.2C
3.8 + 0.6C
1.4 ±1.7
0.9 ± 0.4
0.8 ± 0.3
0.8 ± 0.3C
14.6 ± 3.2°
14.3 ±2.5
12.7 ±1.9
14.5 ±2.0
6.2 ±4.0
4.7 ±3.7
3.9 ±4.1
6.1 ±4.3
2.4 ±1.5
1.7±1.0
2.1 ±1.0
1.2 ±0.3
26.7 ± 4.4
27.8±4.7d
25.7 ± 3.5C
26.6 ± 3.lc
42.3 ± 7.2C
44.2 ± 7.8C
46.5 ± 6.7C
45.6 ± 7.8C
4.7 ±1.0
5.5 ±1.8
6.0 ±1.5
4.9 ± 2.3
0.7 ± 0.4
0.7 ± 0.5
0.5 ±0.1
0.5 ±0.1
10.1 ±0.5
11.2±1.0
10.7 ±0.6
11.7 ±0.6
3.2 ±1.6
2.8 ±1.0
2.5 ± 0.5
2.5 ± 0.4
1.7 ±0.9
1.5 ±1.6
1.0 ±0.2
0.9 ± 0.2
22.5 ±4.5
18.8 ±2.8
18.4 ±3.2
20.7 ± 2
54.4 ± 6.0
57.7 ± 4.7
58.9 ±3.0
58.3 ±3.7
6.4 ±1.6
7.3 ±1.3
8.1 ±1.1
4.6 ± 0.6
vaiuto aic invalid -l. O
d p < 0.01, c p < 0.001.
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hepatitis and primary biliary cirrhosis III, showed
increased concentrations of free cholesterol, which were
probably related to the well-known decreased activity of
lecithin : cholesterol acyltransferase in this pathologic
state (5-7). In the acute viral hepatitis group, increased
levels of triacylglycerols were observed in agreement
with previous results (34). In contrast, patients with liver
cirrhosis had decreased plasma levels of triacylglycer-
ols, mainly due to a marked decrease in the number of
VLDL particles. We found in previous work that VLDL
from cirrhotic patients had an altered apolipoprotein
composition, with a very low content of apolipoprotein
E (34-36), which probably indicates a reduced pro-
duction of VLDL by the liver in this disease. In addition,
Tab. 5 Fatty acid composition of phospholipids from total plasma
and lipoproteins in patients with hepatobiliary diseases and con-
trols.
Plasma samples were subjected to sequential ultracentrifugation for
lipoprotein isolation. The lipids were extracted and separated by
TLC and the fatty acid composition was evaluated as methyl esters
by GLC.
Uncompen-
sated liver
cirrhosis
(n = 7)
Compen-
sated liver
cirrhosis
(n = 5)
Primary
biliary
cirrhosis in
stages I, II
(n = 8)
Primary
biliary
cirrhosis in
stage III
(n = 6)
Acute
viral
hepatitis
(n = 5)
Other
intrahepatic
cholestasis
(n = 5)
Controls
(n = 6)
Myristic acid C14 : 0 (%)a
VLDL 0.4 ± 0.2
LDL 0.8 ± 0.4
HDL 1.1 ±0.8
Total plasma 0.7 ± 0.3C
Palmitic acid C16 : 0 (%)a
VLDL
LDL
HDL
Total plasma
31.5±1.8
32.8 ±2.0
28.4 ± 2.2
31.1 ±1.9
Palmitoleic acid C16 : 1 (%)a
VLDL 1.4 ±0.6
LDL 1.8±0.8C
HDL 1.8 ±0.6
Total plasma 1.5±0.6C
StearicacidC18:0(%)a
VLDL . 16.3 ±0.4
LDL 14.0 ±3.1
HDL 14.1 ±3.2
Total plasma 15.3 ±0.8
01eicacidC18:l (%)a
VLDL 18.3±1.8d
LDL 20.2 ± 3.8d
HDL 21.9±2.7e
Total plasma 19.5±2.5e
LinoleicacidC18:2(%)a
VLDL 23.5 ±1.2
LDL 21.4 ±2.7
HDL 21.5 ±4.5
Total plasma 22.8 ±3.1
Eicosatrienoic acid C20 : 3ω6 (%)a
VLDL 1.8 ±1.2
LDL 2.5 ±1.7
HDL 2.4 ±1.6
Total plasma 1.9 ±0.9
0.3 ±0.1
0.5 ±0.1
0.3 ±0.1
0.5 ±0.1
32.0 ± 6.2
32.7 ±3.4
32.6 ± 6.8
32.9 ± 3.6
1.9±0.4C
1.3 ±0.9
1.5±0.7C
1.8±0.2d
14.0 ±3.6
13.7 ±3.4
12.8 ± 5.0
14.0 ±2.8
21.9 ±8.4
21.6 ±8.6
20.9 ±6.1
20.7 ± 4.4
22.1 ±7.4
23.1 ±7.2
23.8 ± 9.7
21.6 ±5.7
2.1 ±0.6
1.5 ±0.9
1.5±l.lc
1.9 ±0.5
0.4 ±0.1
0.4 ±0.1
0.4 ±0.1
0.3 ±0.1
30.8 ± 3.9
34.6 ±4.1
32.3 ±3.8
33.1 ±3.4
1.2 ±0.5
0.7 ± 0.6
1.0 ±0.8
0.6 ± 0.5
16.7 ±2.8
16.1 ±2.5
15.9 ±1.7
16.9 ±2.6
13.9 ±2.2
12.3 ±3.3
12.8 ±3.0
12.9 ±2.1
25.2 ± 6.8
24.9 ± 5.8
24.6 ± 6.5
25.9 ± 8.3
2.1 ±1.2
2.4 ±1.9
2.7 ±1.6
2.4 ±1.6
0.6 ± 0.3
0.4 ±0.1
0.5 ± 0.3
0.7 ± 0.4
30.1 ±3.3
35.6 ±4.8
31.4 ±4.9
32.5 ±4.4
1.1 ±0.8
1.9 ±1.2
1.0 ±0.7
16.8 ±2.0
16.3 ±5.4
15.7 ±2.5
15.2 ±2.9
14.2 ±4.4
13.0 ±5.3
12.0 ±4.1
12.2 ±3.3
25.9 ± 7.2
32.1 ±7.8
26.4 ± 6.8
25.2 ± 5.0
2.2 ± 0.9
2.4 ± 0.8
2.5 ± 0.6
2.7 ±1.1
1.1 ±0.9
0.5 ± 0.3
0.5 ± 0.2
0.5 ±0.3
31.2 ±2.0
33.1 ±2.6
30.3 ±1.4
31.8 ±2.0
1.9 ±1.4
0.9 ± 0.4
1.2±0.5C
1.3 ±'0.5
17.2±0.9C
16.5 ±0.7
16.8 ±1.2
16.0 ±0.4
17.2 ±3.0°
15.2 ±3.9
15.8±3.1C
16.1 ±3.4
18.8±2.0C
20.0 ± 2.7
20.6 ±2.1
21.0 ±2.1
2.4 ±1.2
3.1 ±1.3
3.5 ±1.2
3.2 ±0.9
0.3 ±0.1
0.4 ± 0.3
0.9 ± 0.5C
0.4 ± 0.2
31.7±4.3
32.1 ±2.7
32.0 ±4.8
32.9 ± 2.5
1.0 ±0.6
0.9 ± 0.7
0.9 ± 0.5
1.3 ±0.9
17.8 ±3.3
16.9 ±2.8
16.9 ±2.5
17.2 ±2.1
14.8 ±4.3
14.5 ±4.3
14.5 ± 2.2
15.4 ±2.4
21.5 ±4.6
21.7 ±2.4
20.4 ±3.5
20.1 ±3.8
4.2 ±1.1
4.3 ±1.6
4.9 ± 0.6
4.1 ± 1.5C
0.5 ± 0.2
0.4 ±0.1
0.3 ±0.1
0.3 ±0.1
30.4 ±3.1
33.8 ±3.4
30.3 ±1.6
34.3 ± 2.5
0.9 ±0.2
0.7 ± 0.3
0.7 ± 0.2
0.8 ± 0.2
16.1 ±0.8
15.6 ±0.7
16.3 ±0.9
16.5 ±1.2
12.8 ±1.9
12.8 ±1.9
11.9±1.9
12.9 ±1.9
24.3 ± 2.2
22.8 ±1.8
22.9 ±1.9
23.0 ±1.5
3.0±1.1
3.1 ±1.5
3.1 ±0.7
2.3 ± 0.6
Arachidonic acid C20 : 4 (%)a
VLDL
LDL
HDL
Total plasma
6.7 ± 2.5C
6.2±3.2C
7.6±2.8C
7.0±2.2C
5.1±3.4d
5.5±2.1d
5.9±1.5d
6.6 ± 2.6C
9.6 ±3.6
7.9 ±2.3
9.9 ±3.3
8.7 ±1.9
8.9±1.6C
7.9 ± 2.2
9.8 ± 2.6
9.0 ± 2.9
9.2±l.lc
9.0 ±1.4
10.8 ±1.3
9.3 ±1.9
9.0 ±2.1
8.9 ±1.9
9.7 ± 2.5
8.4 ±2.7
12.1 ±2.1
11.3 ±2.4
12.5 ±3.1
10.2 ±1.8
a
 Values are means ± S. D. Significance differences between groups and control a t c ρ < 0.05,
d p < 0.01, c p < 0.001.
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we observed that the LDL-triacylglycerol concentration
is increased in these patients as compared with controls.
Actually, LDL from these patients appear to be enriched
with respect to triacylglycerols because of the elevated
LDL triacylglycerol cholesterol mass ratio. No Lp-X
was detected in the LDL fraction by agarose electropho-
resis (data not shown). Whether the decreased unsatura-
tion of fatty acids in the lipids of these lipoproteins con-
tributes directly to the altered metabolism of LDL in
these patients deserves further investigation.
In conclusion, in a broad group of patients with liver
cirrhosis or other related pathologies, we demonstrated
profound changes in plasma lipid levels and lipoprotein
distribution, and a diminished content of linoleic acid as
indicative of the undernourished state of some of these
patients. Despite these alterations, triacylglycerols and
cholesteryl esters were homogeneously distributed
among the different plasma lipoproteins in cirrhotic pa-
tients as well as in normal individuals. This indicates
that the plasma cholesteryl ester transfer protein activity
present in these conditions is high enough to promote a
rapid exchange of these lipids between the lipoproteins
and it demonstrates the possible importance of extrahep-
atic synthesis of cholesteryl ester transfer protein.
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